Vancomycin

Therapeutic

Treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains

Structural features

SMILES

C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O

Sequence

-

Molar mass

1449.27 g/mol

Constitutional members:

N.A.

Natural amino acids

N.A.

D-Amino acids

N.A.

N-terminus

CH3

C-terminus

COOH

Cyclic

yes

Members/cycle

multicyclic

Bond to form cycle

C-C; C-O

Lipidation

no

Glycosylation

yes - 2 sugars

Route of administration

IV, ORAL

Terminal half-life

6 hours

Protein binding

0.5

Absorption and Bioavailability

Oral vancomycin has a bioavailability of less than 10%. Onset of action: Vancomycin has a rapid onset of action with a serum peak concentration immediately following the completion of the intravenous infusion.

References